Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †
Authors:
- Yu-Te LinYLYu-Te Lin
- Yi-Chung WuYWYi-Chung Wu
- Gwo-Ching SunGSGwo-Ching Sun
- Chiu-Yi HoCHChiu-Yi Ho
- Tzyy-Yue WongTWTzyy-Yue Wong
- Ching-Huang LinCLChing-Huang Lin
- Hsin-Hung ChenHCHsin-Hung Chen
- Tung-Chen YehTYTung-Chen Yeh
- Chia-Jung LiChia-Jung Li
- Ching-Jiunn TsengCTChing-Jiunn Tseng
- Pei-Wen ChengPCPei-Wen Cheng
Open Access
- 5 October 2018
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (10) , 329
Abstract
Recent studies have indicated that several anti-hypertensive drugs may delay the development and progression of Alzheimer’s disease (AD). However, the relationships among AD, hypertension, and oxidative stress remain to be elucidated. Here, we aimed to determine whether reactive oxygen species (ROS) reduction by resveratrol in the brain leads to cognitive impairment reduction in rats with angiotensin II (Ang-II)-induced early AD. Male Wistar Kyoto (WKY) rats with Ang-II-induced AD were treated with losartan or resveratrol for two weeks. Our results show decreased blood pressure, increased hippocampal brain-derived neurotrophic factor (BDNF) level, and decreased nucleus tractus solitarius (NTS) ROS production in the Ang-II groups with losartan (10 mg/kg), or resveratrol (10 mg/kg/day) treatment. Furthermore, losartan inhibition of hippocampal TauT231 phosphorylation activated AktS473 phosphorylation, and significantly abolished Ang-II-induced Aβ precursors, active caspase 3, and glycogen synthase kinase 3β (GSK-3β)Y216 expressions. Consistently, resveratrol showed similar effects compared to losartan. Both losartan and resveratrol restored hippocampal-dependent contextual memory by NADPH oxidase 2 (NOX2) deletion and superoxide dismutase 2 (SOD2) elevation. Our results suggest that both losartan and resveratrol exert neuroprotective effects against memory impairment and hippocampal damage by oxidative stress reduction in early stage AD rat model. These novel findings indicate that resveratrol may represent a pharmacological option similar to losartan for patients with hypertension at risk of AD during old age.Keywords
All Related Versions
Funding Information
- National Science Council (MOST104-2320-B-075B-003-MY3, MOST106-2320-B075B-001)
This publication has 56 references indexed in Scilit:
- The Coming of Age of the Angiotensin Hypothesis in Alzheimer’s Disease: Progress Toward Disease Prevention and Treatment?Journal of Alzheimer’s Disease, 2018
- p38 MAPK Inhibition Improves Synaptic Plasticity and Memory in Angiotensin II-dependent Hypertensive MiceScientific Reports, 2016
- Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer’s DiseaseJournal of Alzheimer’s Disease, 2015
- Angiotensin and Neurovascular Coupling: Beyond HypertensionMicrocirculation, 2015
- Nitric oxide and geriatrics: Implications in diagnostics and treatment of the elderlyJournal of Geriatric Cardiology, 2011
- Resveratrol modulates astroglial functions: neuroprotective hypothesisAnnals of the New York Academy of Sciences, 2011
- AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid-β Peptide MetabolismJournal of Biological Chemistry, 2010
- Resveratrol bioavailability and toxicity in humansMolecular Nutrition & Food Research, 2010
- Sirtuins as Novel Targets for Alzheimer's Disease and Other Neurodegenerative Disorders: Experimental and Genetic EvidenceJournal of Alzheimer’s Disease, 2010
- Opportunities and limitations of genetic analysis of hypertensive rat strainsJournal Of Hypertension, 2009